Combating Bacterial Infection with Metabolism-Regulating Nanomaterials Authors: Danqing Yu, Qionghong Ma, Bangxun Mao, Songping Yu, Yanni Song, Chunhui Dai, Dongliang Yang, Xuyang Chen Published: 2026 ABSTRACT AbstractThe rise of antibiotic resistance presents a major global health challenge. Bacterial survival is closely tied to their metabolic reprogramming under stress, which enhances their environmental adaptability. While current antibacterial strategies are often limited by bacterial resistance, nanomaterials offer a promising alternative due to their unique physicochemical properties. These functionalized nanoagents can precisely deliver antimicrobials and selectively interfere with metabolic processes of bacteria, including aerobic and anaerobic metabolism, peptidoglycan synthesis, metal ion homeostasis, and nitrogen metabolism. By interfering with energy metabolism, nutrient uptake, and quorum sensing, they can effectively eliminate drug-resistant and persister bacteria. In this review, we summarize the recent advances in metabolic-regulating antibacterial treatment. Then, the clinical translation challenges facing nanotechnology—driven metabolic regulation strategies are discussed. Finally, we hope this review offers forward-looking perspectives on the development of non-antibiotic antibacterial nanoagents for future bacterial metabolic interventions. Introduction Bacterial infections remain a severe and persistent threat to global health.1,2 The World Health Organization has explicitly identified antibiotic resistance as one of the top ten public health threats facing humanity.3,4 According to current estimates, without effective interventions, drug-resistant bacterial infections could cause approximately 10 million deaths globally each year by 2050, with economic losses reaching $100 trillion.5 Current clinical practice remains heavily dependent on conventional antibiotics, yet decades of overuse and misuse have precipitated a worldwide superbug crisis.6,7 The emergence and spread of drug-resistant bacteria—such as carbapenem-resistant enterobacteriaceae and methicillin-resistant Staphylococcus aureus (MRSA)—have progressively neutralized the therapeutic effect of antibiotics, bringing humanity closer to a post-antibiotic era.8 The escalating challenge of bacterial resistance not only increases treatment failure rates, prolongs hospital stays, and drives up medical costs, but also undermines the foundations of modern healthcare systems.9,10 Therefore, developing innovative antibacterial strategies that operate beyond traditional killing mechanisms to combat drug-resistant pathogens has become an urgent global priority. The survival, reproduction, and pathogenicity of bacteria are deeply intertwined with their intricate intracellular metabolic networks.11–13 These metabolic processes not only supply energy and biosynthetic precursors for bacterial growth but also directly regulate the expression of virulence factors, biofilm formation, and antibiotic tolerance.11,14–16 Modulating bacterial metabolism and reshaping intracellular physiology influence both the cellular uptake of antibiotics and their target-specific susceptibility. For instance, by promoting the conversion of pyruvate to formate, which increases bacterial membrane permeability to antibiotics.17 Additionally, metabolic reprogramming can counteract resistance-associated defense pathways (ie, suppressing antibiotic-degrading enzymes), thereby potentiating the overall antibacterial efficacy.14 Consequently, targeting bacterial metabolism—termed “metabolic reprogramming”—has emerged as a highly promising strategy for combating bacterial infections.14 Unlike conventional bactericidal approaches, metabolic interference offers multiple advantages. For example, it can suppress bacteria by nutrient deprivation or disruption of their defense mechanisms, enhancing the efficacy of traditional antibiotics;18,19 it effectively targets dormant persister cells and biofilm-embedded bacteria,20,21 addressing key clinical challenges in eradicating stubborn infections. Moreover, metabolic interference strategy can synergize with existing therapeutic strategies, creating new opportunities for revitalizing conventional antibacterial methods through combinatorial repurposing.17,22 In the rapidly evolving field of antibacterial research, nanomaterials have emerged as an up-and-coming solution due to their unique physicochemical properties and multifunctional capabilities.23–25 Through rational design, these materials can function not only as efficient drug delivery vehicles or direct antibacterial agents, but also as active regulators capable of precisely interfering with core metabolic pathways in bacteria.26–28 Such metabolism-targeting nanomaterials enhance antibacterial efficacy through multiple mechanisms, including disrupting energy metabolism, hijacking essential nutrients, and interfering with quorum-sensing systems, thereby establishing a promising platform for precise and efficient antimicrobial therapy.29,30 Despite several reviews on antibacterial nanoagents,31,32 bacterial metabolism in relation to drug resistance,13,14,33,34 metabolism-guided antibiotic discovery,27 no systematic review has yet focused on antibacterial nanoagents with metabolic modulation functions. To address this gap, this review begins by systematically examining the core challenges confronting current bacterial infection therapies. Then we summarize the recent progress in nanomaterials to enhance antibacterial treatment through metabolic modulation (Scheme 1), which includes aerobic and anaerobic metabolism, metal ion metabolism, peptidoglycan synthesis, and quorum-sensing systems, among others. Since previous reviews have covered the molecular mechanisms of metabolic regulation in bacterial growth, biofilm formation, and resistance reversal, here we will not revisit them and direct readers to those references.14,21,33,34 Finally, we discuss the clinical translation challenges facing nanotechnology-driven metabolic regulation strategies. Through this comprehensive analysis, we hope to provide innovative design principles for next-generation antibacterial strategies. Scheme 1Metabolic-regulatory nanomaterials for anti-infection therapy. The arrow pointing indicates the next product.A diagram illustrating antimicrobial nanoagents with metabolic regulatory functions. It includes sections on different metabolic processes: Anaerobic metabolism shows glucose converting to lactate and 2 ATP via anaerobic respiration, with glycolysis and fermentation pathways. Aerobic metabolism depicts electron transport and ATP synthesis. Metal ion metabolism features Fe superscript 3 plus and Cu superscript 2 plus. Nitrogen metabolism includes a chemical equation involving glucose and ammonia. Peptidoglycan metabolism displays a synthesis pathway. Quorum sensing involves signaling molecules and biofilm formation. The central section highlights antimicrobial nanoagents with metabolic regulatory functions.A diagram of antimicrobial nanoagents with metabolic regulatory functions in various metabolic processes. Metabolic-regulatory nanomaterials for anti-infection therapy. The arrow pointing indicates the next product. Nanostrategies for Regulating Bacterial Metabolism Aerobic Metabolism Bacterial energy metabolism is a continuous process centred on redox reactions. Initially, the cell breaks down substrates, such as glucose, via pathways like glycolysis, producing a limited amount of adenosine triphosphate (ATP) and reducing electron carriers, including nicotinamide adenine dinucleotide (NADH).35 These electrons then enter the membrane-bound electron transport chain, where they pass through carriers including quinones and cytochromes, releasing energy in a stepwise manner.36 This energy drives the pumping of protons (H⁺) across the membrane, establishing an electrochemical gradient.37 Finally, protons flow back through ATP synthase along this gradient, releasing energy that powers the synthesis of ATP from adenosine diphosphate (ADP) and inorganic phosphate.38 Meanwhile, electrons are transferred to a terminal acceptor, such as oxygen, thereby completing both the energy conversion and redox cycles.39 Therefore, modulating aerobic metabolic pathways such as the tricarboxylic acid cycle and electron transport chain can enhance antibacterial efficacy against metabolically active bacteria. Aerobic metabolism directly affects the proton kinetic potential and membrane potential of bacteria, thereby regulating the intracellular uptake of antibiotics; meanwhile, electron transfer interference can induce an explosion of reactive oxygen species (ROS) to destroy bacterial macromolecules and enhancing antibacterial efficacy. Nicotinamide Adenine Dinucleotide Homeostasis The metabolism of NADH is central to bacterial life.40 It acts as a key coenzyme that not only drives the respiratory chain to synthesize ATP but also maintains redox homeostasis within the cell.41 Disrupting NADH metabolism directly depletes bacterial energy and induces oxidative stress, leading to cell death.42 Consequently, targeting this pathway has emerged as a promising strategy for developing new antibacterial agents. For example, Wen et al synthesized chitosan-modified ultra-small platinum nanoparticles (CSPA), which mimic NADH dehydrogenase activity to degrade NADH and inhibit ATP synthesis.43 CSPA exhibits potent antibacterial activity at very low concentrations (eg, 2 μg/mL against Escherichia coli (E. coli)), inhibits biofilm formation, and shows a low risk of inducing bacterial resistance. Therefore, the antibacterial efficacy can be enhanced by integrating NADH-targeting with other therapeutic modalities. For instance, Wang et al developed nitric oxide (NO)-donor (Ru-NO) functionalized copper and nitrogen co-doped graphene quantum dots (Cu, N-GQDs@Ru-NO).44 Cu, N-GQDs@Ru-NO not only exhibits NADH dehydrogenase-like activity with 30 times higher catalytic efficiency than copper-free analogues, but also releases NO and generates a photothermal effect under near-infrared (NIR) light. This multi-modal attack reduces bacterial ATP content by 83.5%, achieving near-complete eradication of MRSA and effectively clearing biofilms. To further boost catalytic performance, the same team further constructed Cu, Fe, S, N-GQDs@Ru-NO bimetallic nanozyme (Figure 1A).45 The copper-iron synergy enhanced ROS generation and NADH oxidation capacity (with a turnover number of 4.62) (Figure 1B and C). Combined with photothermal and gas therapies, this system demonstrated excellent efficacy in eradicating MRSA biofilms (greater than 99% eradication) and promoting wound healing in infected wounds. Figure 1(A) The preparation process of Cu, Fe, S, N-GQDs@Ru-NO nanozyme and its anti-infective mechanism. (B) Characterization of ROS production capacity. (C) NADH consumption capacity of Cu, Fe, S, N-GQDs@Ru-NO. Reproduced with permission.45 Copyright 2026, Elsevier. (D) The synthesis route of AP@Bi2S3 and its antibacterial action via disrupting the bacterial membrane, photocatalytic antibacterial and NADH metabolism interference. (E) NADH consumption, photocarriers, and O2– generation mechanism of Bi2S3. (F) Characterization of the NADH removal capability of AP@Bi2S3 (× represents obstruction, ↓ represents decrease, ↑ represents increase). Reproduced with permission.27 Copyright 2024, American Chemical Society.The infographic illustrates a nanozyme and phototherapy platform for antibacterial wound healing. It highlights mechanisms like reactive species generation and bacterial metabolism disruption. The layout consists of two main blocks: left (A-C) and right (D-F). Panel A shows the synthesis of Cu, Fe, S, N-GQDs at Ru-NO, depicting processes like PTT, PDT, CDT and membrane destruction. Panel B presents absorbance spectra over time (320-420 nm), showing peak shifts. Panel C shows similar spectra (240-400 nm) with trends in absorbance. Panel D outlines the synthesis of AP at Bi2S3, showing antibacterial action and metabolism disturbance. Panel E details the Bi2S3 NPs mechanism involving NIR and redox disturbance. Panel F displays absorbance changes over time (240-400 nm), indicating NADH to NAD+ conversion.Infographic on nanozyme and phototherapy for antibacterial wound healing, showing mechanisms. (A) The preparation process of Cu, Fe, S, N-GQDs@Ru-NO nanozyme and its anti-infective mechanism. (B) Characterization of ROS production capacity. (C) NADH consumption capacity of Cu, Fe, S, N-GQDs@Ru-NO. Reproduced with permission.45 Copyright 2026, Elsevier. (D) The synthesis route of AP@Bi2S3 and its antibacterial action via disrupting the bacterial membrane, photocatalytic antibacterial and NADH metabolism interference. (E) NADH consumption, photocarriers, and O2– generation mechanism of Bi2S3. (F) Characterization of the NADH removal capability of AP@Bi2S3 (× represents obstruction, ↓ represents decrease, ↑ represents increase). Reproduced with permission.27 Copyright 2024, American Chemical Society. Beyond metal nanozymes, NADH-targeting strategies combined with other functional nanomaterials also show great potential. Wang et al developed a sprayable agent of antibacterial polypeptosome (APs@Bi2S3) (Figure 1D).27 Through self-assembling and in situ decoration strategy, photocatalytic Bi2S3 nanoparticles (~6.5 nm) was loaded in the core of positively charged polypeptide bodies from a poly(ε-caprolactone)-block-poly(glutamic acid)-block-poly(Lys-stat-Phe) triblock copolymer. Under NIR light, photogenerated electrons from Bi2S3 efficiently oxidize bacterial NADH, disrupting energy metabolism (Figure 1E and F). This photocontrol strategy achieved a greater than 99% kill rate against MRSA and E. coli, and significantly accelerated wound healing in mice. Electron Transport Chain In bacteria, the electron transport chain serves as the core hub for energy production.46 This system, embedded in the cell membrane, uses protein complexes, including NADH dehydrogenase and cytochromes, to channel electrons from donors such as NADH. The energy from this electron transfer pumps protons outward, creating a gradient that fuels ATP synthesis by ATP synthase, which provides the energy for cellular processes.47 In addition, this physiological process maintains the cell’s critical redox balance. Given its critical role, targeting the bacterial electron transfer process has emerged as a promising approach for antibacterial strategies. For example, Tan et al constructed a schottky heterojunction film made of Au/MgFe-metal oxide (Au/MgFe-MMO) (Figure 2A).48 Au/MgFe-MMO actively captures protons and electrons from the bacterial respiratory chain, thereby collapsing the proton motive force (PMF) (Figure 2B). By blocking ATP synthesis, it induces bacterial death through energy starvation. Simultaneously, the material triggers severe oxidative stress, increasing intracellular ROS levels by more than tenfold. Experiments demonstrate that Au/MgFe-MMO achieves an in vitro antibacterial rate exceeding 99.97% against Staphylococcus aureus (S. aureus) and E. coli, and a 95.42% in vivo rate in a rat infection model. It also significantly promotes bone integration without affecting mammalian mitochondrial function, highlighting its excellent selective antibacterial potential. Figure 2(A) The preparation process of Au/MgFe-MMO film. (B) Au/MgFe-MMO-mediated starvation therapy by disrupting proton and electron transfer. Reproduced with permission.48 Copyright 2025, American Association for the Advancement of Science. (C) The bactericidal mechanism of CS-MoS2 nanosheets (× represents obstruction, ↓ represents decrease, ↑ represents increase). Reproduced with permission.49 Copyright 2019, American Chemical Society.An infographic with three sections: A, B and C. Section A shows a preparation route from a Ti substrate and FeOOH layer through hydrothermal reaction to MgFe-LDH film, then calcination to MgFe-MMO and sputtering to Au/MgFe-MMO, labeled as 0D/2D Au/Mg-Fe mixed oxides heterojunction. Section B contrasts Normal and Smart surfaces under ′Cell′ with mitochondria and bacteria icons. The ′Active′ side shows orderly proton-electron transfer with ATP, ADP, NADH, NAD+, H2O and O2. The ′Starved′ side shows interference in transfer with red marks. Section C depicts a bacterium with labels: CS-MoS2 sheet, Membrane Attachment, Puncturing, Damage, Depolarization, Cytoplasmic Leakage, Metabolic Arrest, ATP Production, Respiratory dehydrogenase, ROS, Oxidative Stress, DNA damage, GSH, GSSG and Inactivation. Three boxes at the bottom indicate Membrane Depolarization and Disruption, Intracellular Oxidative Stress and Metabolic Arrest, leading to Cell Death.An infographic schematic of Au/MgFe-MMO film preparation and antibacterial energy starvation effects. (A) The preparation process of Au/MgFe-MMO film. (B) Au/MgFe-MMO-mediated starvation therapy by disrupting proton and electron transfer. Reproduced with permission.48 Copyright 2025, American Association for the Advancement of Science. (C) The bactericidal mechanism of CS-MoS2 nanosheets (× represents obstruction, ↓ represents decrease, ↑ represents increase). Reproduced with permission.49 Copyright 2019, American Chemical Society. In another study, Guan et al developed a multi-metal galvanic cell metasurface (GCMS) based on biocompatible metals, including Zr/Ti/Ta.50 Using plasma immersion ion implantation and sputtering techniques, they constructed a nanopillar array. This structure leverages the asymmetric electric potential between metals to generate a continuous electron flow, enhancing electrocatalytic activity. The GCMS disrupts bacterial extracellular electron transfer, blocks proton transport and ATP generation, and concurrently catalyzes ROS production. This dual assault of oxidative stress and energy depletion results in an antibacterial rate of over 99.99% against S. aureus and E. coli. In rabbit models, GCMS implants tripled the bone torque (to 150 N·mm), showcasing superior dual functionality in antibacterial efficacy and bone promotion. Beyond direct electron capture, other strategies focus on manipulating the local microenvironment to enhance bacterial killing. Jannesari et al reported a reduced graphene oxide/copper peroxide (rGO/CuO2) nanocomposite that acts as a controlled-release nano-shuttle for oxygen nanobubbles (O2 NBs) to disrupt respiration.51 In this design, CuO2 serves as a solid oxygen source, with rGO extending the release duration of O2 NBs from 60 to 144 hours. The conductive rGO also captures electrons from the respiratory chain and transfers them to the O2 NBs, enabling the localized generation of ROS, such as hydroxyl radical (•OH) and singlet oxygen. Under NIR laser irradiation, rGO/CuO2 exhibits a photothermal effect that further promotes O2 NB release and rupture, causing mechanical damage to bacterial membranes. At 125 μg/mL with laser irradiation, rGO/CuO2 nearly completely inhibited S. aureus (~99%) and achieved an 89.5% inhibition rate for E. coli, demonstrating a powerful antibacterial effect. Regulation of Respiratory Chain Dehydrogenase The dehydrogenases in the bacterial respiratory chain are located on the cell membrane and are the key initiating step in the aerobic respiration process of bacteria.52,53 They function by catalyzing the dehydrogenation of substrates, such as glucose and succinate, and transferring the released electrons to downstream carriers.54 This process drives proton pumps to establish a transmembrane proton gradient, which is ultimately used to synthesize ATP—the universal energy currency of the cell.55 Consequently, the activity of these enzymes directly governs the efficiency of bacterial energy metabolism and cellular viability. In recent years, some nanomaterials have been demonstrated to effectively inhibit bacterial metabolism by targeting dehydrogenase activity. For example, Roy et al synthesized positively-charged chitosan-modified MoS2 nanosheets (CS-MoS2, +16.6 mV) via a green, chitosan-assisted ultrasonic exfoliation method.49 CS-MoS2 electrostatically binds to and embeds within bacterial membranes, forming depressions that lead to rapid membrane depolarization and loss of integrity. Further studies revealed that CS-MoS2 significantly interferes with the dehydrogenases of the respiratory chain; at the minimum inhibitory concentration (MIC), lactate dehydrogenase activity in E. coli and S. aureus was reduced by ∽50% and 35%, respectively, leading to a general metabolic arrest (Figure 2C). The treatment also induced a substantial rise in intracellular ROS—a threefold increase in E. coli at 6×MIC—and decreased the activity of the antioxidant glutathione (GSH) by 25% in E. coli. CS-MoS2 exhibited potent bactericidal activity against both Gram-negative (E. coli, MIC 30 μg/mL) and Gram-positive (S. aureus, MIC 90 μg/mL) bacteria. Furthermore, at 2.5×MIC, it reduced S. aureus biofilm activity by 80%. Apart from CS-MoS2, other nanomaterials also show potential by targeting dehydrogenases. Wang et al synthesized eco-friendly Mg(OH)2 nanoparticles (M-NPs) using a co-precipitation method.56 M-NPs with an average size of 43.1 ± 13.4 nm and a high surface oxygen vacancy content (18.1 μmol L−1) generate ROS and release hydroxide anion under both dark and light conditions, creating an alkaline environment. Mechanistically, M-NPs severely disrupt the metabolic processes of E. coli, particularly by inhibiting the activity of respiratory chain dehydrogenases. At 5.0 mg mL−1, enzyme activity dropped sharply from 0.95 ± 0.08 to 0.13 ± 0.05, crippling bacterial energy production. The antibacterial effect was dose-dependent, achieving a 100% antibacterial rate at a concentration of 5.5 mg mL−1. The MIC50 and MIC90 values were 0.5 mg mL−1 and 5.0 mg mL−1, respectively, and a concentration of 5.0 mg mL−1 produced an inhibition zone of 16.16 ± 0.73 mm, confirming that M-NPs effectively induce bacterial death by disrupting the metabolic processes. Anaerobic Metabolism Bacteria initiate anaerobic metabolism in response to various environmental cues, with the core trigger being an oxygen-deficient or anoxic environment.57 When oxygen—the terminal electron acceptor—is lacking, facultative anaerobes sense the decreasing concentration through regulatory proteins such as Fnr system.58 This prompts a rapid shutdown of aerobic respiration genes and a shift to anaerobic pathways to sustain energy production. Specific strategies include using alternative electron acceptors, such as nitrate, sulfate, ferric ions, or carbonate, in anaerobic respiration, or employing fermentation, where organic compounds serve as both electron donors and acceptors to regenerate NAD⁺ and produce ATP.59 Metabolic flexibility enables bacteria to thrive in hypoxic niches, such as the host intestine, deep‑seated infected tissue, and bacterial biofilms.60 Notably, this anaerobic mechanism has been ingeniously applied for bacterial clearance, particularly against biofilm infections. For instance, Xiu et al developed oxygen-deprived nanoparticles (HCM NPs) by using hyaluronic acid to co-deliver the photosensitizer chlorin e6 (Ce6) and the antibiotic metronidazole (MNZ).61 HCM NPs employ photodynamic therapy (PDT) to consume oxygen and exacerbate hypoxia within the biofilm. The hypoxic environment triggers anaerobic metabolism in MRSA, leading to the overexpression of nitroreductase and subsequent activation of MNZ (Figure 3A). This “PDT-activated chemotherapy” strategy demonstrated a powerful synergistic effect. In vitro, HCM NPs with laser irradiation achieved a 99.9998% (5.9-log) reduction in MRSA biofilm viability. The efficacy was even higher in a subcutaneous infection model (99.99996%, 6.4 log units) and a diabetic mouse chronic wound model (99.999999%, 8.0 log units). Furthermore, the treatment promoted M2 macrophage polarization, accelerating tissue repair and highlighting the potential of manipulating the hypoxic microenvironment to enhance antibacterial outcomes. Figure 3(A) The preparation of HCM and its activation of the antibacterial drug MNZ by inducing nitroreductase expression through photodynamic oxygen consumption. Reproduced with permission.61 Copyright 2022, Springer Nature. (B) Preparation of PLCM NPs and their application in activating MNZ and enhancing immunity through photodynamically-mediated anaerobic metabolism (× represents obstruction, ↓ represents decrease, ↑ represents increase). Reproduced with permission.26 Copyright 2025, American Chemical Society.The diagram illustrates two processes involving nanoparticles. In section A, HA-Ce6-MNZ NPs are shown with components: quenched chlorin e6, metronidazole and hyaluronic acid. A 635 nm laser targets MRSA biofilm, leading to photodynamic therapy and oxygen consumption, causing inflammation. Hypoxia activates MNZ, eradicating biofilm and promoting tissue healing. Section B depicts PLCM NPs with components: DOTAP, Ce6, MNZ, DSPE-PEG and PFP. Ultrasound stimulation targets PAO1 biofilm in lungs, enhancing drug penetration and immune activation. Oxygen consumption and reactive oxygen species lead to hypoxia, activating MNZ and glycolysis-mediated inflammatory activation. The diagram includes metabolic pathways: glycolysis, TCA cycle and oxidative phosphorylation, with HIF-1 alpha involvement.Diagram: HCM & PLCM NPs activate MNZ using photodynamic & ultrasound for antibacterial & immune responses. (A) The preparation of HCM and its activation of the antibacterial drug MNZ by inducing nitroreductase expression through photodynamic oxygen consumption. Reproduced with permission.61 Copyright 2022, Springer Nature. (B) Preparation of PLCM NPs and their application in activating MNZ and enhancing immunity through photodynamically-mediated anaerobic metabolism (× represents obstruction, ↓ represents decrease, ↑ represents increase). Reproduced with permission.26 Copyright 2025, American Chemical Society. In a subsequent study, the same team developed ultrasound-responsive liposome nanoparticles (PLCM NPs).26 PLCM NPs co-encapsulated Ce6, MNZ, and perfluoropentane, using sonodynamic therapy (SDT) to intensify the hypoxic conditions within biofilms. This approach not only induced anaerobic metabolism in Pseudomonas aeruginosa (P. aeruginosa) to activate MNZ but also promoted immune cell glycolysis via the HIF-1α pathway, thereby boosting the inflammatory immune response (Figure 3B). This metabolic regulation strategy achieved a remarkable 7.1-log (99.999993%) reduction in biofilm bacteria in vitro. And it reduced the bacterial load in a mouse chronic lung infection model by 4.8 log (99.999%), demonstrating synergistic antibacterial and immunomodulatory effects. The above researches indicate that the strategic use of responsive nanomaterials to manipulate the local microenvironment and induce bacterial anaerobic metabolism offers a breakthrough in combating biofilm resistance and deep-seated infection with a hypoxic environment. Furthermore, this methodology also holds broad and promising applications in immune modulation and tissue regeneration. Metal Ion Metabolism Cu Metabolism Interference Copper ions are crucial trace elements in bacteria, serving as essential cofactors for enzymes like cytochrome c oxidase in the respiratory chain, superoxide dismutase (SOD), and multi-copper oxidases.62,63 These proteins are vital for aerobic energy synthesis, ROS clearance, and substrate oxidation. To maintain this delicate balance, copper homeostasis is tightly regulated by efflux pumps, which prevent toxic damage from the Fenton reaction.64 However, when exogenous copper overload or homeostatic failure occurs, intracellular Cu⁺ accumulates and catalyzes the Fenton reaction, generating •OH.65 This leads to lipid peroxidation, inactivation of iron-sulfur cluster proteins, and damage to the respiratory chain, ultimately triggering bacterial cuproptosis.66 Leveraging this mechanism, some copper ion-inference strategies have been developed. For instance, Chen et al constructed polyethylene glycol-functionalized copper-tannic acid nanoparticles (PCT NPs) that intelligently release Cu2⁺ in acidic microenvironments (Figure 4A).67 The release of Cu2⁺ triggers a Fenton-like reaction, depletes GSH, and generates abundant ROS, inducing bacterial cuproptosis via inducing the expression of cuproptosis-related genes and oxidative damage (Figure 4B–D). PCT NPs exhibit strong bacterial surface adhesion, further enhancing copper ion targeting. In vitro, PCT NPs reduced MRSA viability by 6.9 log units (The concentration of copper ions is 4 μg/mL). In vivo, PCT NPs decreased bacterial loads in skin and lung infections by nearly 3.0 and 2.2 log units, respectively, while promoting wound healing and reducing inflammation. Figure 4(A) The preparation process of PCT NPs and their antibacterial mechanism. (B) Heatmap imaging of differentially expressed genes after PCT NPs treatment. (C) Analysis of bacterial membrane permeability using the o-Nitrophenyl-β-D-galactopyranoside probe. (D) Malondialdehyde (MDA) levels in MRSA Following Treatment (↓ represents decrease, ↑ represents increase, *P < 0.05, **P < 0.01, ***P <0.001). Reproduced with permission.67 Copyright 2025, Elsevier.A scientific figure with four parts: 1) Polyethylene glycol-functionalized copper-tannic acid nanoparticles are synthesized using copper ions, tannic acid and polyethylene glycol at 60 degrees C with ammonia. These nanoparticles target skin and lung infections in mice, inducing oxidative stress and bacterial damage. 2) A heatmap displays gene expression differences among control, tannic acid and copper-tannic acid nanoparticle groups, with the latter showing strong upregulation in genes related to copper ion transport and oxidative stress. 3) A bar chart compares treatment groups (H2O, tannic acid, copper ions and copper-tannic acid nanoparticles) with OD 420 values, where copper-tannic acid nanoparticles have the highest value near 0.14, indicating significant effects. 4) Another bar chart shows malondialdehyde concentration, a marker of oxidative damage, with the copper-tannic acid nanoparticles group having the highest value near 9, indicating the greatest oxidative damage.Scientific figure: PCT NPs prep, antibacterial action, gene heatmap, bar charts of bacterial damage markers. (A) The preparation process of PCT NPs and their antibacterial mechanism. (B) Heatmap imaging of differentially expressed genes after PCT NPs treatment. (C) Analysis of bacterial membrane permeability using the o-Nitrophenyl-β-D-galactopyranoside probe. (D) Malondialdehyde (MDA) levels in MRSA Following Treatment (↓ represents decrease, ↑ represents increase, *P < 0.05, **P < 0.01, ***P <0.001). Reproduced with permission.67 Copyright 2025, Elsevier. Recently, our team has developed several copper-based antibacterial nanozymes for infected wound treatment by inducing bacterial cuproptosis-like death. For burn infection wound management, Ag-CuO bimetallic nanozymes were developed via a liquid-phase method.68 Ag-CuO produces ROS via multi-enzyme activity and downregulates the phosphotransferase system and the TCA cycle, thus suppressing bacterial energy acquisition and ATP production. In addition, it downregulates the lpdA gene, synergistically promoting the influx and accumulation of Cu2+, significantly enhancing bacterial cuproptosis and inhibiting biofilm formation. By using ROS-starvation-cuproptosis-like death combined antibacterial strategy, Ag-CuO nanozymes not only exhibited potent antibacterial efficacy over commercial silver dressings in burn-infected wounds. For diabetic infected wounds, we have developed a Ce2O@CuxOS-based intelligent ROS‑regulating platform.69 Under light irradiation, it efficiently generates ROS and releases copper ions within the acidic infected microenvironment, synergistically disrupting bacterial redox homeostasis, interfering with the tricarboxylic acid cycle, and inducing bacterial cuproptosis. In the dark, Ce2O@CuxOS exerts the activity of catalase to remove excess ROS, reduces host injury, and induces M2-type macrophage polarization, thus enabling a fine-tuned transition from antimicrobial to anti-inflammatory action and presenting an innovative therapeutic method for wound healing. In another study, Hu et al designed mucin-permeable Cu2O-BSO NPs for treating acute bacterial pneumonia. Cu2O-BSO NPs release copper ions at the infection site while the integrated GSH synthesis inhibitor (buthionine sulfoximine, BSO) synergistically depletes bacterial GSH.70 This dual action disrupts the redox balance, inducing a bacterial cuproptosis phenotype characterized by downregulation of tricarboxylic acid cycle, elevated lipid peroxidation, and inhibited respiratory chain activity. The Cu2O-BSO NPs demonstrated MICs of 250 µg/mL and 500 µg/mL against MRSA and P. aeruginosa PAO1, respectively, increasing intracellular ROS and malondialdehyde (MDA) levels by ≥5.8-fold and ≥3.4-fold. In a MRSA pneumonia model, Cu2O-BSO treatment boosted mouse survival to 60% and significantly alleviated lung infection and inflammation. In the treatment of osteomyelitis, Li et al developed CFE@CM nanocells (~100 nm) using a biomimetic membrane derived from bone marrow mesenchymal stem cells to coat Cu–Fe-ELC peroxide.71 This platform features infection microenvironment responsiveness, the ability to self-supply H2O2, and bone marrow targeting. Under acidic conditions, it releases Cu2⁺/Fe2⁺ and the copper carrier (bis(thiohydrazide) amide, ELC), synergistically enhancing the Fenton reaction. This process disrupts iron-sulfur clusters and the tricarboxylic acid cycle, inducing cuproptosis. At pH 6.0, the MIC against MRSA was as low as 25 µM (in Cu), and the material effectively inhibited biofilm formation. After 15 days of treatment, bone density in mice with osteomyelitis nearly normalized, and inflammation was significantly reduced. RNA-seq confirmed the mechanism, showing interference with key pathways, including copper metabolism and oxidative phosphorylation. Beyond delivering metal ions, chelation can also influence bacterial metal metabolism by reducing the concentration of specific target ions. Recently, Fang et al prepared hollow copper-rich Prussian blue nanostructures (Cu-HMPBs), which release Cu2⁺ in a weakly acidic environment (16% release rate after 12 hours) and selectively chelate Fe2⁺ within bacteria to induce iron starvation.72 The intracellular Cu content in bacteria increased by 53.4 times, while the Fe content decreased by 1.72 times, jointly exacerbating protein toxicity stress and redox imbalance. This dual effect significantly enhances the bacterial cuproptosis. For instance, Cu-HMPBs can achieve a 99.9% bactericidal rate at an extremely low dose (2 μg/mL of Cu ions) and reduce the bacterial load by approximately 7 logarithms in a diabetic wound model. Within 20 days, the wound closure rate reached 98%, demonstrating excellent ability to eliminate drug-resistant bacteria and promoting healing capabilities. Iron Metabolism Interference Iron ions are fundamental to bacterial life, serving as crucial cofactors in essential processes.73 They integrate into respiratory chain complexes (eg, cytochromes, NADH dehydrogenases) and the enzymes of the tricarboxylic acid cycle (eg, aconitase) by forming iron-sulfur clusters and heme groups.74,75 These iron-containing substances drive electron transfer, energy metabolism, and oxidative phosphorylation. Simultaneously, iron acts as the active center of catalase and peroxidase, enabling the clearance of ROS and maintaining redox homeostasis.76 Furthermore, Iron ions function as an environmental signal, regulating a network of genes involved in iron acquisition, storage, and virulence throughout bacterial growth, adaptation, and pathogenesis.77,78 To maintain intracellular homeostasis, the uptake, storage, and utilization of iron are tightly regulated.79 However, an imbalance in iron metabolism—such as from excessive exogenous iron or weakened antioxidant defenses—can lead to bacterial ferroptosis.80 Through the Fenton reaction, free Fe2⁺ catalyzes rampant lipid peroxidation, causing membrane damage, metabolic enzyme inactivation, and an explosive accumulation of ROS.81 This mechanism is highly analogous to eukaryotic ferroptosis and plays a significant role in antibiotic stress. Given the critical role of iron metabolism in bacterial survival, a novel antibacterial strategy has been developed that precisely targets iron homeostasis to achieve potent antibacterial efficacy. Ga3⁺ acts as an iron “Trojan horse”, competitively inhibiting iron metabolism, downregulating iron transport genes, and impairing SOD activity.82 For instance, Ding et al explored the synergy between iron chelation and antibiotics. They developed a gallium-doped layered double hydroxide (Ga-LDH) nanosheet for the delivery of deferiprone (DFP) and ceftazidime (Cefi) (Figure 5A).83 In an acidic environment, DFP@Ga-LDH-Cefi releases Ga3⁺ and DFP, thereby reducing the iron content in P. aeruginosa to 19.34% through competitive substitution of Ga3⁺ and chelation of DFP, which further decreases the Fe/Ga ratio and inhibits iron-dependent metabolism and antioxidant defense (eg, reducing catalase activity by 70%). With a MIC of 48 μg/mL, DFP@Ga-LDH-Cefi significantly reduced the bacterial load in a mouse implant infection model and delayed the development of resistance. Figure 5(A) Schematic illustrating the preparation of DFP@Ga-LDH-Cefi and its therapeutic mechanism against implant infections with hematoma, which operates by concurrently depleting environmental iron and delivering the antibiotic Cefi. Reproduced with permission.83 Copyright 2024, Wiley. (B) Synthesis of PG3M@GaPP for enhanced antibacterial effect by Fe3⁺ interference-augmented photodynamic elimination of intracellular bacteria. (C) The antimicrobial principle of gallium ions. (D) The principle of Calcein for detecting intracellular iron ions within bacteria. (E) Macrophages subjected to various treatments were visualized by fluorescence imaging after being stained with Calcein (× represents obstruction, ↓ represents decrease, ↑ represents increase). Reproduced with permission.84 Copyright 2025, American Chemical Society.The diagram has five sections, A to E. Section A details DFP@Ga-LDH-Cefi preparation and its anti-infection mechanism, highlighting bacterial iron uptake, hematoma-induced iron environment and bacterial metabolism intervention. It involves deferiprone iron scavenging, gallium substitution and enhanced cefiderocol uptake. Section B shows PG3M@GaPP synthesis and immune modulation in mice, illustrating healthy to infected transitions and intracellular antibacterial activity via a 532 nm laser. Section C compares bacterial proliferation strategies, including the enhanced Trojan horse strategy using gallium ions. Section D presents calcein detecting intracellular iron ions in bacteria. Section E displays fluorescence images of macrophages treated with varying iron ion and GaPP concentrations, showing different fluorescence levels.Diagram: Ga-LDH-Cefi & PG3M@GaPP strategies for iron depletion & immune modulation in mice. (A) Schematic illustrating the preparation of DFP@Ga-LDH-Cefi and its therapeutic mechanism against implant infections with hematoma, which operates by concurrently depleting environmental iron and delivering the antibiotic Cefi. Reproduced with permission.83 Copyright 2024, Wiley. (B) Synthesis of PG3M@GaPP for enhanced antibacterial effect by Fe3⁺ interference-augmented photodynamic elimination of intracellular bacteria. (C) The antimicrobial principle of gallium ions. (D) The principle of Calcein for detecting intracellular iron ions within bacteria. (E) Macrophages subjected to various treatments were visualized by fluorescence imaging after being stained with Calcein (× represents obstruction, ↓ represents decrease, ↑ represents increase). Reproduced with permission.84 Copyright 2025, American Chemical Society. To tackle intracellular infection, Zhou et al synthesized PG3M@GaPP nanoflower, which is composed of a mannose-modified poly-L-lysine dendrimer polymer (PPG3M) loaded with a gallium-porphyrin IX complex (GaPP) (Figure 5B).84 By using mannose-mediated macrophage, PG3M@GaPP enhances the clearance of intracellular bacteria. In an acidic microenvironment, Fe3⁺ competes with Ga3 to displace it in GaPP, forming a more stable FePP and releasing Ga3⁺, thereby further strengthening the Trojan horse effect (Figure 5C) and removing intracellular Fe3⁺ (Figure 5D and E). Under 532 nm laser irradiation, at a concentration of 50 μg/mL, PG3M@GaPP achieved a 96.35% bactericidal rate against intracellular S. aureus. At a dose of 50 mg/kg, it achieved a 100% survival rate in mice with intracellular bacterial infections. In the treatment of diabetic infected wound, Hou et al combined Lactobacillus plantarum (LP) with glucose oxidase-loaded iron-based nanozyme to construct LP@FeG compound material.85 The cascade reaction between probiotics and glucose oxidase consumes local glucose in the wound, lowers pH, and generates H2O2, thereby activating the peroxidase-like activity of nanozymes and generating a large amount of ROS; At the same time, Fe3⁺ enters the interior of bacteria, inducing iron-dependent lipid peroxidation accumulation and membrane damage. Thus, LP@FeG can efficiently kill drug-resistant bacteria (ie, MRSA). In vivo experiments showed that LP@FeG not only achieves nearly 100% bactericidal rate, but also has significant anti-inflammatory and angiogenic effects, providing a new strategy for the management of diabetic wound hyperglycemia and drug-resistant infection. These studies reveal that precisely regulating iron metabolism and synergistically combining it with ROS damage and immune regulation can effectively enhance antibacterial efficacy and circumvent drug resistance, offering a robust and multifaceted platform for anti-infective nanomedicine. Nitrogen Metabolism Nitrogen metabolism underpins both the survival and pathogenic potential of pathogens.86,87 These pathogens adeptly assimilate and utilize various nitrogen sources from the host environment—such as amino acids, urea, and ammonium salts—not only to fuel their proliferation but also to intricately link nutrient acquisition with virulence.87 For instance, the catabolism of amino acids, such as arginine and glutamine, can directly generate or modulate virulence factors, thereby disrupting the host’s local physiological balance.88,89 Concurrently, this process yields immune-modulating molecules, such as polyamines and NO, enabling bacteria to evade or counteract host immune responses and establish a dominant position within the infection niche.90,91 This metabolic dependency also presents a promising target for novel antibacterial strategies. In the study by Gajera et al, a colloidal silver nanoparticle formulation (Silversol®) effectively disrupted multidrug-resistant P. aeruginosa.92 At a sub-inhibitory concentration (1 ppm, below its MIC of 1.5 ppm), the formulation disrupted the bacterial nitrogen metabolic network, leading to a 37% increase in nitrate accumulation and a significant upregulation of 10 denitrification pathway genes, including norB, nirS, and nosZ, thereby inducing nitrosative stress. Silversol also perturbed iron homeostasis, increasing the production of the siderophore pyoverdine by 48% and enhancing bacterial hemolytic activity. Furthermore, it inhibited biofilm formation by 19%, cleared pre-formed biofilms by 34%, and reversed bacterial resistance to augmentin. These findings collectively demonstrate that Silversol® compromises bacterial adaptability and virulence through synergistic disruption of nitrogen metabolism. Serine can be converted to pyruvate by the serine deaminase.93 This pyruvate then enters central carbon metabolism, directly contributing to the production of ATP and NADH.94 Furthermore, this pathway is closely linked to one-carbon metabolism, providing the necessary formyl and methyl groups for purine/thymidine synthesis,95 as well as various methylation reactions. This connection significantly influences bacterial antioxidant capacity (eg, by regulating GSH synthesis) and their adaptive responses to nutrient stress or host environments, playing a crucial regulatory role in bacterial growth, biofilm formation, and pathogenicity.96 Given the central role of serine metabolism, researchers are now exploring it as a target for metabolic intervention in antibacterial strategies. For instance, Huang et al developed a polyamino acid-based nanomedicine named FAlsBm@Rif with a cascading targeting function.97 This system utilizes a serine (Ser) and mannose (Man) functionalized poly(N-acryloyl phenylalanine)-b-poly(2-((4-formylbenzyl)oxy) acrylic acid ethyl ester)-b-poly((S)-2-acrylamido-3-(4-boronphenyl) propionic acid) (FAlB) polymer as a carrier to encapsulate the antibiotic rifampicin (Rif) (Figure 6A). FAlsBm@Rif NPs are efficiently internalized by macrophages via mannose-mediated endocytosis. Within the acidic lysosomal environment, they release Ser and expose boronic acid groups, enabling precise anchoring to persistent staphylococcal peptidoglycan. This delivery strategy achieves localized co-delivery of Ser and Rif to the bacteria. The released Ser undergoes dehydration and deamination to form pyruvate. The resulting pyruvate activates the fermentative metabolic pathway in persistent bacteria, substantially increasing their ATP and NADH content (Figure 6B–E), as well as their proton motive force (PMF). Consequently, it effectively reverses the stringent response and alleviates cell wall stress, thereby resensitizing the resistant bacteria to antibiotics. Experimental results demonstrated that FAlsBm@Rif achieves a clearance rate of up to 99.78% in an intracellular persistent infection model, significantly outperforming Rif alone (63.41%). It also exhibits a 99.29% bactericidal efficiency in vitro, highlighting its great potential for reversing bacterial resistance through metabolic reprogramming and enhancing antibiotic efficacy. Figure 6(A) Preparation of intracellular persister-targeting FAlsBm@Rif NPs and their antibacterial mechanism by releasing Ser to enhance persister sensitivity to RIF. ATP levels in (B) planktonic and (C) intracellular persisters. The intracellular (D) levels and (E) ratios of NADH and NAD+ (× represents obstruction, ↓ represents decrease, ↑ represents increase, *P < 0.05, **P < 0.01, ***P <0.001). Reproduced with permission.97 Copyright 2025, American Chemical Society.The infographic illustrates the preparation and mechanism of FAlsBm@Rif nanoparticles targeting intracellular S. aureus persisters. At the top, it shows the synthesis and functionalization of nanoparticles with serine, mannose and phenylboronic acid groups. The middle section depicts macrophage uptake via CD206 receptors, lysosome escape and on-site delivery leading to persistence reversal. The intracellular mechanism schematic highlights changes in fermentation, proton motive force and metabolic pathways. The bottom row contains bar charts labeled B to E. Chart B shows ATP levels in planktonic cells, with higher levels in normal compared to persisters. Chart C shows intracellular ATP levels, with FAlsBm treatment increasing ATP. Chart D presents NADH and NAD concentrations, with FAlsBm increasing NADH. Chart E shows the NADH/NAD ratio, with FAlsBm treatment resulting in a higher ratio. Statistical significance is indicated by asterisks: P < 0.05, P < 0.01, P < 0.001.FAlsBm@Rif nanoparticles target S. aureus, showing synthesis, macrophage uptake, ATP/NADH data. (A) Preparation of intracellular persister-targeting FAlsBm@Rif NPs and their antibacterial mechanism by releasing Ser to enhance persister sensitivity to RIF. ATP levels in (B) planktonic and (C) intracellular persisters. The intracellular (D) levels and (E) ratios of NADH and NAD+ (× represents obstruction, ↓ represents decrease, ↑ represents increase, *P < 0.05, **P < 0.01, ***P <0.001). Reproduced with permission.97 Copyright 2025, American Chemical Society. Through NO synthase or denitrification pathways, pathogenic bacteria generate endogenous NO, leveraging it as a signaling molecule to orchestrate the expression of virulence genes and their metabolic adaptations. NO is a multifaceted signaling molecule that regulates bacterial physiology by modifying transcription factors, such as MgrA and OxyR, to mediate virulence, antioxidant defense, biofilm formation, and metabolic adaptation. In addition, NO can exert toxicity by binding to metal cofactors in respiratory chain complexes and ribonucleotide reductase, which disrupts energy metabolism and enhances the efficacy of aminoglycoside antibiotics. For example, Wang et al developed a dual-metal Ga/Cu methylimidazolium-based MOF (Van@Ga/Cu-MOF) nanozyme, which has a high specific surface area for the loading of vancomycin (Van) and can serve as a dual-metal ion storage reservoir to release Ga3⁺ and Cu2⁺ continuously. Ga/Cu-MOF inhibits endogenous NO production by Ga3⁺ (reducing NO levels by 40.16%) and promotes the decomposition of S-nitrosourea (RSNO) by Cu2⁺ (reducing RSNO levels by 32.65%) through reducing the nitrosylation of the virulence factor mgrA, thereby significantly reducing the tolerance of MRSA to Van and inducing bacterial cuproptosis (Figure 7A–E).22 In terms of antibacterial efficacy, the combination of Ga/Cu-MOF and Van has a killing rate of approximately 98.66% against MRSA, and achieves nearly complete bacterial clearance in mouse skin infection and rat osteomyelitis (reaching 99.20% and 99.14%, respectively), while effectively regulating the inflammatory response and promoting tissue healing. By targeting bacterial metabolism and programmed cell death, this strategy offers a novel approach to overcoming multidrug-resistant infections. Figure 7(A) The preparation of Van@Ga/Cu-MOF nanozyme and its enhanced antibacterial activity of Van by inhibiting endogenous NO generation and facilitating RSNO depolymerization. (B) NO and (C) RSNO level change after treatment with different concentrations of Ga/Cu-MOF. (D) The change of S-nitrosylated proteins after Ga/Cu-MOF (right channel) treatment. (E) The antibacterial activity of Van, Ga/Cu-MOF, and Van@Ga/Cu-MOF (× represents obstruction, ↓ represents decrease, ↑ represents increase, *P < 0.05, **P < 0.01, ***P <0.001). Reproduced with permission.22 Copyright 2025, Elsevier.The image A shows the preparation of Van@Ga/Cu-MOF using Ga, Cu, PVP, 2-MI and H3btc through a solvothermal method, followed by vancomycin addition. The process targets MRSA, causing ferroptosis and cuproptosis, inhibiting biofilm and eliminating bacteria. The bottom section illustrates skin defect infection and osteomyelitis treatment in a mouse model, highlighting the antibacterial and healing effects of Van@Ga/Cu-MOF. The image B shows a bar graph of NO levels (micromolar) decreasing with increasing Ga/Cu-MOF concentration (microgram per milliliter). The image C shows a bar graph of RSNO levels (nanogram per milliliter) decreasing with increasing Ga/Cu-MOF concentration. The image D shows a gel with bands indicating changes in S-nitrosylated proteins, specifically MgrA. The image E shows a bar graph of CFUs normalized by control, comparing control, Van, Ga/Cu-MOF and Van@Ga/Cu-MOF, with significant reductions in CFUs for Van@Ga/Cu-MOF.A composite image showing Van@Ga/Cu-MOF preparation, antibacterial effects and related data on NO and RSNO levels. (A) The preparation of Van@Ga/Cu-MOF nanozyme and its enhanced antibacterial activity of Van by inhibiting endogenous NO generation and facilitating RSNO depolymerization. (B) NO and (C) RSNO level change after treatment with different concentrations of Ga/Cu-MOF. (D) The change of S-nitrosylated proteins after Ga/Cu-MOF (right channel) treatment. (E) The antibacterial activity of Van, Ga/Cu-MOF, and Van@Ga/Cu-MOF (× represents obstruction, ↓ represents decrease, ↑ represents increase, *P < 0.05, **P < 0.01, ***P <0.001). Reproduced with permission.22 Copyright 2025, Elsevier. Peptidoglycan Metabolism The metabolism of peptidoglycan is a dynamic and core process in bacteria, maintaining cell wall integrity through a precise equilibrium of synthesis and hydrolysis.98 This cycle starts inside the cell, where monomers are synthesized and then shuttled to the periplasm. Enzymes such as transglycosylases and transpeptidases cross-link these new strands into the existing network, thereby conferring structural strength and shape to the protein.99 To accommodate this expansion, autolysins carefully cleave the old peptidoglycan layer, enabling cell elongation and division. The critical importance of this balance is underscored by its vulnerability; disruption leads to cell lysis, making it a prime target for β-lactam antibiotics.100 With the widespread application of nanomaterials in the field of antibacterial, their mechanism of action has gradually expanded to precise intervention in bacterial structure. For instance, Markowska et al investigated the effects of silver nanoparticles (2–35 nm) on Listeria monocytogenes.101 They found that while sub-inhibitory concentrations of AgNPs did not directly curb bacterial growth, they significantly enhanced bacterial lysis induced by lysozyme or Triton X-100 and accelerated the autolysis rate of isolated peptidoglycan. Furthermore, AgNPs treatment increased cell membrane permeability, leading to the leakage of intracellular substances (such as DNA and proteins). These results collectively indicate that AgNPs exert antibacterial effects by disrupting the integrity of the cell wall and membrane. This disruption affects the activity of peptidoglycan hydrolases (autolysins), thereby breaking the dynamic balance between peptidoglycan synthesis and hydrolysis and ultimately triggering cell lysis. Therefore, AgNPs exert their effect on peptidoglycan metabolism through an indirect, destructive mechanism. Compared with the indirect interference strategy, researchers have recently begun using structural simulation to regulate peptidoglycan metabolism with greater precision. For example, Feng et al developed sophisticated poly(D-amino acid)-based nanoparticles (FA NPs).102 FA NPs self-assemble with a hydrophobic core of D-phenylalanine segments and a hydrophilic shell of D-aminoacrylic acid segments. The key to their design is the surface’s precise display of the α-amino and α-carboxyl groups of D-aminoacrylic acid, enabling it to mimic the precursor structure of bacterial peptidoglycan. The study confirmed that FA NPs are specifically inserted into the peptidoglycan network of S. aureus via transpeptidation mediated by peptidoglycan-binding protein 4 (PBP4) (Figure 8A). Rather than causing direct cell lysis, this insertion disrupts the normal synthesis and cross-linking of peptidoglycan, further compromising the stability of anchored extracellular polymer matrices, such as amyloid fibers (Figure 8B), and ultimately leading to biofilm dissociation. Thus, by using molecular mimicry and the precise targeting of the peptidoglycan synthesis, FA NPs exhibit a potential antibacterial effect. Figure 8(A) The preparation of FA NPs and their mechanism for biofilm eradication via disruption of peptidoglycan synthesis. (B) Fluorescent imaging of live bacteria and amyloid-like fibers using Syto9 and Congo Red probes, respectively. Reproduced with permission.102 Copyright 2024, American Chemical Society.A scientific figure with two panels. The first panel illustrates D-aminoalanine and D-phenylalanine forming monomers that self-assemble into FA nanoparticles with a hydrophobic core and hydrophilic corona. Arrows indicate FA nanoparticles being taken up, integrating into peptidoglycan via PBP4, disrupting peptidoglycan synthesis, damaging extracellular polymeric substance stability and disassembling biofilms. Labels include amyloid-like fiber, peptidoglycan, Staphylococcal cytoplasm and extracellular polymeric substance stability. The second panel features twelve fluorescence micrographs in two rows and four columns. The top row uses Syto9 staining and the bottom row uses Congo Red staining. Columns compare S. epidermidis 12.1 and S. aureus Mu12 with and without nanoparticles. In the presence of nanoparticles, Syto9 signals are reduced and Congo Red signals are altered compared to the absence of nanoparticles. Scale bar is 30 micrometers.Two-panel figure: FA nanoparticle assembly schematic and fluorescence micrographs with/without NPs. (A) The preparation of FA NPs and their mechanism for biofilm eradication via disruption of peptidoglycan synthesis. (B) Fluorescent imaging of live bacteria and amyloid-like fibers using Syto9 and Congo Red probes, respectively. Reproduced with permission.102 Copyright 2024, American Chemical Society. Quorum Sensing Bacteria synthesize and release specific autoinducer molecules through metabolic pathways.103 When the population density reaches a threshold, these signal molecules activate receptor complexes, triggering the quorum-sensing (QS) system to regulate the expression of target genes.104 This regulation coordinates quorum behaviors, while simultaneously controlling the utilization of carbon and nitrogen sources, energy distribution, and secondary metabolic fluxes.105 This transformation of metabolic strategies from individual survival to group collaboration ultimately enhances the adaptability and competitive advantage of bacteria in complex environments.106 Given the crucial role of QS in bacterial cooperative behavior and metabolic regulation, interfering with this process has become an essential strategy for combating P. aeruginosa biofilm infections. For example, Chen et al designed an anti-CD54@Cur-DA NPs with active targeting ability and pH responsiveness.29 Anti-CD54@Cur-DA NPs use electrostatic self-assembly to encapsulate the hydrophobic QS inhibitor curcumin (Cur) within the poly(amidoamine) dendrimer and modify its surface with anti-CD54 antibody, thereby achieving specific targeting to infection sites (the inflamed endothelial cells with high CD54 expression). In an acidic biofilm microenvironment (pH 6.0), the nanoparticles undergo charge reversal (Zeta potential changes from −5.1 mV to +20.5 mV) and size reduction (hydrodynamic diameter decreases from 93.9 nm to 13.1 nm), significantly enhancing their biofilm penetration ability and promoting the release of Cur (more than 50% released within 24 hours). In terms of inhibiting QS, anti-CD54@Cur-DA NPs shows superior efficacy compared to free Cur, for example, reducing the production of violacein to 59.0% (free Cur was 86.8%), significantly down-regulating QS-related genes (eg, LasR, LasI) and signaling molecules (eg, N-hexanoyl-DL-Homoserine lactone reduced by 40.3%), while lowering extracellular polymeric substances (EPS) (to 58.3%) and alginate (to 58.4%), effectively interfering with bacterial metabolism and biofilm formation. In terms of antibacterial efficacy, Anti-CD54@Cur-DA NPs significantly enhance the effectiveness of various antibiotics by down-regulating genes related to drug efflux pumps (eg, mexA, mexB). When used in combination with tobramycin (TOB), Anti-CD54@Cur-DA can reduce biofilm biomass by 87.3% (TOB alone reduces it by 59.3%); in a chronic pulmonary infection model, this strategy reduces the bacterial load by 98.6% and effectively alleviates the inflammatory response. To further expand the application scope of the QS interference strategy, the Lu team developed a star-shaped antibacterial peptide polymer (SAPP) for the delivery of quercetin (QCT) (Figure 9A).107 QCT@SAPP encapsulates the hydrophobic QCT (with a loading capacity of 11.3% and a loading efficiency of 25.6%) within a positively charged amphiphilic star-shaped polymer, significantly enhancing its water solubility and targeting properties. QCT@SAPP achieves rapid release (80.99% release within 24 hours) in an acidic microenvironment (pH 6.0). QCT@SAPP complex can effectively penetrate the biofilm and selectively adhere to bacteria. By inhibiting the Las and Rhl QS systems of P. aeruginosa, bacterial metabolism and the secretion of virulence factors (Figure 9B–E) were interfered. In vitro antibacterial assay, QCT@SAPP can eliminate 99.996% of the biofilm, reducing the biofilm thickness by 80.3%. In the mouse corneal infection model, the biofilm biomass, average thickness, and biovolume decreased by 78.7%, 77.1%, and 78.7% respectively. Through the down-regulation of pro-inflammatory factors (ie, TNF-α and IL-1β) and enhancement of antioxidant effects, QCT@SAPP effectively restores visual function, demonstrating a synergistic potential for anti-biofilm and anti-inflammatory effects. Figure 9(A) Synthesis of QCT@SAPP and its proposed mechanism for combating P. aeruginosa biofilm-induced keratitis. The changes in biofilm virulence factors, (B) biomass, (C) pyocyanin, (D) violacein, and (E) EPS (× represents obstruction, ↓ represents decrease, ↑ represents increase, *P < 0.05, **P < 0.01, ***P <0.001, n.s.: not significance). Reproduced with permission.107 Copyright 2025, American Chemical Society.The diagram illustrates the synthesis and mechanism of QCT@SAPP in combating biofilm. It shows the assembly of SAPP and QCT into QCT@SAPP, which penetrates biofilm, attaches to bacterial membranes, inhibits quorum sensing and destroys bacteria and biofilm. Inflammation modulation is depicted with IL-1beta and TNF-alpha down-regulation. Graphs B, C, D and E display the effects on biomass, pyocyanin, violacein and EPS, respectively. Biomass is significantly reduced by QCT@SAPP. Pyocyanin and violacein levels decrease, with violacein showing no significance in one comparison. EPS is also reduced. Labels include PAMAM, QCT, QCT@SAPP and P. aeruginosa.Diagram of QCT@SAPP mechanism against biofilm with graphs on biomass, pyocyanin, violacein and EPS. (A) Synthesis of QCT@SAPP and its proposed mechanism for combating P. aeruginosa biofilm-induced keratitis. The changes in biofilm virulence factors, (B) biomass, (C) pyocyanin, (D) violacein, and (E) EPS (× represents obstruction, ↓ represents decrease, ↑ represents increase, *P < 0.05, **P < 0.01, ***P <0.001, n.s.: not significance). Reproduced with permission.107 Copyright 2025, American Chemical Society. Beyond suppressing the QS pathway, modulating the bacterial microenvironment to interfere with its metabolism and cooperative behavior indirectly is another practical approach. For example, Wang et al constructed a copper-based nanosystem coated with a hybrid biomimetic membrane (mCu@CaO2). mCu@CaO2 was prepared through a three-step process: first, CaO2 nanocores were synthesized; then self-assembled with copper ions and 3,3′-dithiobis(propionohydrazide) ligand to form a core-shell Cu@CaO2; and finally, a mixed membrane of red blood cells and platelets was encapsulated to enhance targeting ability.30 mCu@CaO2 can respond to the acidic pH and high GSH levels in the bacterial microenvironment, release O2 and H2O2, and generate highly toxic •OH through a Fenton-like reaction while simultaneously consuming GSH, thereby destroying the bacterial cell membrane and wall structure. In addition, mCu@CaO2 can inhibit the accessory gene regulator ABC (AGR ABC) system of MRSA and the QS systems of P. aeruginosa PAO1, reduce the secretion of toxins, and interfere with the synthesis of staphylococcal flavin by inhibiting the generation of 4, 4-diaponeurosporene, thereby increasing the bacterial sensitivity to H2O2. In vitro antibacterial assay indicates that the MIC of mCu@CaO2 against MRSA, PAO1 and E. coli is 100, 100 and 200 μg/mL (reducing to 50, 50 and 100 μg/mL, respectively, at pH 5.8), it can completely kill bacteria within 2 hours (using 4×MIC for MRSA and E. coli, and 2×MIC for PAO1), and effectively inhibit biofilm formation (inhibition rates reaching 70%, 88.2% and 71% respectively) and destroy mature biofilms (destruction rates being 45.2%, 26.6% and 25.8% respectively). In vivo experiments further confirmed that mCu@CaO2 can significantly reduce bacterial load and levels of inflammatory factors (eg, TNF-α and IL-6) in peritonitis and pneumonia, and promote the repair of infected tissues. Based on the foregoing research, nanomaterials that modulate bacterial QS have demonstrated considerable promise in bacterial infection therapy. Their core advantage lies in the ability to interfere with bacterial communication systems, fundamentally weakening their virulence and disrupting biofilm defenses. This interference strategy is different from traditional sterilization methods and can effectively avoid the development of bacterial resistance. More importantly, nanomaterials with QS regulation performance can significantly enhance the sensitivity of bacteria to drugs. On the one hand, they can inhibit QS, and dismantle the biofilm matrix, allowing antimicrobial agents to penetrate more effectively; On the other hand, nanomaterials themselves can serve as precise drug delivery platforms or synergistically kill bacteria through photothermal, photodynamic, chemodynamic, and other effects. Conclusion and Prospects In summary, the remarkable adaptability of pathogenic bacterial metabolism—closely linked to their survival, proliferation, virulence, and antibiotic tolerance—underscores the critical need to understand its relationship with key pathogenic traits, such as biofilm formation, drug resistance. This understanding makes metabolic intervention a promising approach to combating resistant infections. However, targeting a single pathway is often insufficient due to the inherent redundancy and plasticity of bacterial metabolic networks, which allow bacteria to activate alternative pathways for survival. Engineered nanomaterials offer a robust solution, enabling precise metabolic modulation to enhance antibacterial efficacy and overcome resistance. The advantage of nanomaterials, including high drug-loading capacity, superior target specificity, and multi-modal synergy, collectively underpin improved clinical outcomes. Table S1 exemplifies this potential by summarizing representative metabolism-regulating nanomaterials, along with their mechanisms, limitations, advantages, and antibacterial applications. Although the application of nanomedicine in bacterial metabolic regulation is poised for significant growth, this field remains in its nascent stages. The development of advanced nanomaterials for metabolic intervention presents several pivotal challenges that must be addressed. (1) The complexity of bacterial metabolism and species differences: The diversity and complexity of bacterial metabolism present a significant therapeutic challenge. Metabolic pathways exhibit extensive crosstalk and compensation; for instance, inhibiting glycolysis can prompt bacteria to consume amino acids or fatty acids, evading treatment. Moreover, core metabolic dependencies vary significantly between Gram-positive and Gram-negative bacteria, as well as between free-living and biofilm states, which complicates the development of broad-spectrum strategies. Advancing this field requires a deeper understanding of metabolic interactions under specific infection conditions, such as hypoxia and nutrient stress. Precisely defining the metabolic profiles of common pathogens will be key to developing personalized therapies. Therefore, further basic research is needed to identify these metabolic vulnerabilities and inform the design of effective antibacterial nanomaterials. (2) Selection and optimization of infection models: The convergence of bacterial metabolism research and nanomedicine opens new avenues for precisely targeting infections. Despite this promise, a significant challenge lies in the inherent complexity of the in vivo infection milieu, which is difficult to replicate in experimental settings. Current mainstream models, including in vitro plate cultures and rodent infections, frequently lack the fidelity to simulate key aspects of the human microenvironment, such as nuanced nutrient gradients, host immune pressures, and authentic tissue structures. Although models for biofilm and persistent infection are vital for evaluating the metabolic regulatory effects of nanomaterials, they currently lack standardization. To bridge this gap and more accurately assess therapeutic potential, the field must prioritize the development of advanced infection models. This includes leveraging organoid technology and larger animal models, which can more faithfully recapitulate human physiology and immunology. Such progress is imperative for reliably predicting the clinical application of antibacterial nanomaterials. (3) Advanced nanomaterial design for precision targeting: Targeting bacterial metabolic pathways with nanomaterials is a promising therapeutic strategy, yet its design and preparation present significant challenges. A primary obstacle is ensuring that nanomaterials effectively accumulate at the infection site and are selectively internalized by bacteria, all while evading clearance by host immune cells. This requires precise control over nanomaterial properties, including size, shape, surface charge, and the grafting of targeting ligands (eg, antibodies or phage proteins). Furthermore, nanomaterials are not merely passive carriers for metabolic inhibitors; their intrinsic physicochemical properties—such as enzyme-like activities or the ability to generate ROS—can directly disrupt bacterial metabolism. However, a limited understanding of how these properties precisely alter the bacterial metabolic network hinders the rational design of high-performance agents; whether metabolic‑regulating nanomaterials will cause non-specific interference with the host’s normal microbiota and cellular metabolism during application. Therefore, it is imperative to leverage systems biology and metabolomics to elucidate the interactions between nanomaterials and bacterial metabolism. This knowledge will guide the development of next-generation, intelligent nanobactericides capable of responding to the specific microenvironment of an infection and releasing their payload on demand. (4) Artificial intelligence (AI) driven development of antibacterial nanomaterials: AI has potential application scenarios in the development of antibacterial nanomaterials with metabolic function regulation. Through high-throughput data and machine learning, AI can rapidly predict nanomaterial interactions with bacterial metabolic enzymes, enabling the precise design of nanostructures that disrupt bacterial energy metabolism and biosynthesis. Meanwhile, AI algorithms can simulate the complex metabolic microenvironment within biological membranes, optimize the size, surface charge, and targeted ligands of nanomaterials, ensuring their effective penetration of biological membrane barriers and targeted intervention in metabolic pathways. This data-driven intelligent design paradigm not only significantly shortens the material screening cycle, but also collaborates with QS inhibition strategies to disrupt the antibiotic resistance defense network of bacteria from the metabolic source, providing a precise solution that combines efficient killing and low resistance risk for overcoming multi-drug resistant bacterial infection. (5) Biological safety and drug resistance evolution: While nanomaterials are designed to target bacteria, their potential effects on host cells and the commensal microbiota are a critical concern. A theoretical safety window exists because many core bacterial pathways (eg, folate and cell wall synthesis) are absent in human cells. However, nanomaterials that disrupt energy metabolism (eg, by targeting the respiratory chain) may also damage host mitochondria. Furthermore, the long-term retention of nanomaterials could lead to inflammatory responses, organ damage, or introduce risks from their degradation products. Therefore, to minimize material toxicity as much as possible, biodegradable or metabolizable components should be prioritized during the preparation process.108 Meanwhile, to minimize potential adverse effects in the host, local administration should be prioritized, and if systemic therapy is required, the lowest effective dose should be used. In addition, an even greater challenge is bacterial evolution. The sustained metabolic pressure exerted by nanomaterials may select for resistant strains with adaptive metabolisms and even accelerate the spread of resistance genes. Therefore, comprehensive safety and resistance mitigation strategies must be integrated into the initial design of bactericidal nanomaterials. Although mouse models often show good biocompatibility, rigorous long-term safety studies in larger animal models are essential prerequisites for clinical translation. In addition, because metabolic regulatory nanomaterials are still in early development, clinical translational data remain unavailable, and substantial future efforts are required. (6) Scale-up Production and quality supervision: Despite rapid progress, the clinical translation of antibacterial nanomaterials is hindered by complex quality control and high production costs. To address these challenges and the complexities of nanobiological interactions, a multifaceted strategy has been outlined. First, synthesis processes should be simplified without compromising efficacy to reduce cost and improve batch-to-batch consistency. Second, the development of innovative, controllable nanomanufacturing processes must be prioritized, coupled with the establishment of rigorous quality standards to ensure stability, purity, and potency. Finally, for regulatory success, it is critical to clearly define the nanomaterial’s mechanism of action and demonstrate its superiority over standard therapies in sophisticated infection models. Engaging with regulatory agencies early and incorporating clinical feedback throughout the development process will be essential to align product design with real-world requirements and facilitate approval. Despite numerous challenges, sustained interdisciplinary collaboration will deepen our understanding of nanomaterial-mediated metabolic regulation as an antibacterial strategy. The combination of pathogen-specific metabolic susceptibility and individualized treatment provides a powerful paradigm for the rational design of precise antibacterial interventions. Therefore, the key research direction is to optimize the design of nanomaterials, so that they can simultaneously target multiple metabolic fragile links or synergize with traditional antibiotics, thereby enhancing efficacy and delaying the evolution of drug resistance. This strategy is also extendable to fungal infections by targeting unique metabolic nodes such as ergosterol synthesis. Furthermore, nanocarrier-mediated co-delivery of antifungals and metabolic regulators, combined with targeting resistance mechanisms (eg, efflux pumps), promises to surmount current therapy hurdles and provide novel solutions for fungal infection control.109,110 In the future, this metabolic-regulating antibacterial strategy offers a non‑antibiotic route for personalized therapy.